Emmessar Biotech Nutrition Reports Q2 FY2026 Results: Revenue Dips, Records Quarterly Loss

Emmessar Biotech Nutrition Limited has released its unaudited financial results for the second quarter of the fiscal year 2026, ending September 30, 2025. The company, which operates in the healthcare and real estate sectors, reported a decline in revenue and a shift to loss compared to the previous quarter.

Financial Highlights

Key Points

Revenue and Profitability

• The company's revenue from operations for Q2 FY2026 stood at ₹9.26 lakhs, marking a decrease from ₹13.90 lakhs reported in the previous quarter.
• Emmessar Biotech Nutrition recorded a net loss after tax of ₹3.67 lakhs for Q2 FY2026, contrasting with a net profit of ₹30.55 lakhs in the preceding quarter.
• For the first half of FY2026, the company reported a total revenue of ₹23.16 lakhs and a net profit after tax of ₹26.88 lakhs.

Business Operations

• The company operates in two segments: Healthcare and Rent on leasehold land.

Corporate Governance

• The financial results were reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on November 12, 2025.

Share Capital

• Emmessar Biotech Nutrition's paid-up equity share capital stands at ₹499.61 lakhs, with shares having a face value of ₹10 each.

The company's performance in Q2 FY2026 indicates a challenging period with reduced revenue and a shift to loss. However, the half-yearly results remain positive, suggesting potential volatility in the company's quarterly performance.